WO2009068602A2 - Oral care compositions comprising casein, ovalbumin, whey or soy protein - Google Patents

Oral care compositions comprising casein, ovalbumin, whey or soy protein Download PDF

Info

Publication number
WO2009068602A2
WO2009068602A2 PCT/EP2008/066314 EP2008066314W WO2009068602A2 WO 2009068602 A2 WO2009068602 A2 WO 2009068602A2 EP 2008066314 W EP2008066314 W EP 2008066314W WO 2009068602 A2 WO2009068602 A2 WO 2009068602A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
oral care
acid
casein
ovalbumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/066314
Other languages
French (fr)
Other versions
WO2009068602A3 (en
Inventor
Michele Emily Barbour
Robert Peter Shellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to US12/744,881 priority Critical patent/US20110052507A1/en
Priority to EP08853669A priority patent/EP2214695A2/en
Priority to CA2706800A priority patent/CA2706800A1/en
Priority to JP2010535375A priority patent/JP2011504910A/en
Priority to AU2008328832A priority patent/AU2008328832A1/en
Priority to BRPI0820367 priority patent/BRPI0820367A2/en
Priority to MX2010005922A priority patent/MX2010005922A/en
Publication of WO2009068602A2 publication Critical patent/WO2009068602A2/en
Publication of WO2009068602A3 publication Critical patent/WO2009068602A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018Hydrolysed proteins; Derivatives thereof from animals from milk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Tooth mineral is composed predominantly of calcium hydroxyapatite, Ca 1 O(PO 4 )O(OH) 2 , which may be partially substituted with anions such as carbonate or fluoride, and cations such as zinc or magnesium. Tooth mineral may also contain non-apatitic mineral phases such as octacalcium phosphate and calcium carbonate.
  • compositions containing protein for use according to the invention may be prepared by admixing the ingredients in the appropriate relative amount in any order that is convenient, and if necessary adjusting the pH to give a desired value for example from pH 5.5 to 9.0, suitably from pH 6.5 to 7.5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear caused by subsequent exposure to acid.

Description

Novel Use
The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear caused by subsequent exposure to acid.
Tooth mineral is composed predominantly of calcium hydroxyapatite, Ca1O(PO4)O(OH)2, which may be partially substituted with anions such as carbonate or fluoride, and cations such as zinc or magnesium. Tooth mineral may also contain non-apatitic mineral phases such as octacalcium phosphate and calcium carbonate.
Tooth loss may occur as a result of dental caries, which is a multifactorial disease where bacterial acids such as lactic acid produce sub-surface demineralisation that does not fully remineralise, resulting in progressive tissue loss and eventually cavity formation. The presence of a plaque biofϊlm is a prerequisite for dental caries, and acidogenic bacteria such as Streptococcus mutans may become pathogenic when levels of easily fermentable carbohydrate, such as sucrose, are elevated in the oral cavity for extended periods of time.
Even in the absence of cariogenic disease, loss of dental hard tissue can occur as a result of acid erosion and/or physical tooth wear; these processes are believed to act synergistically. Exposure of the dental hard tissues to acid causes demineralisation, resulting in surface softening and a decrease in mineral density. Under normal physiological conditions, demineralised tissues self-repair through the remineralising effects of saliva. Saliva is supersaturated with respect to calcium and phosphate, and in healthy individuals saliva secretion serves to wash out the acid challenge, and raises the pH so as to alter the equilibrium in favour of mineral deposition.
Dental erosion (i.e. acid wear) is a surface phenomenon that involves demineralisation, and ultimately complete dissolution of the tooth surface by acids that are not of bacterial origin. Most commonly the acid will be of dietary origin, such as citric acid from fruit or carbonated drinks, phosphoric acid from cola drinks and acetic acid such as from vinegar. Dental erosion may also be caused by repeated contact with hydrochloric acid (HCl) produced by the stomach, which may enter the oral cavity through an involuntary response such as gastroesophageal reflux, or through an induced response as may be encountered in sufferers of bulimia.
Physical tooth wear is caused by attrition and/or abrasion. Attrition occurs when tooth surfaces rub against each other, a form of two-body wear. An often dramatic example is that observed in subjects with bruxism, a grinding habit where the applied forces are high, and is characterised by accelerated wear, particularly on the occlusal surfaces. Abrasion typically occurs as a result of three-body wear and the most common example is that associated with brushing with a toothpaste. In the case of fully mineralised enamel, levels of wear caused by commercially available toothpastes are minimal and of little or no clinical consequence. However, if enamel has been demineralised and softened by exposure to an erosive challenge, the enamel becomes more susceptible to tooth wear. Dentine is much softer than enamel and consequently is more susceptible to wear. Subjects with exposed dentine should avoid the use of highly abrasive toothpastes, such as those based on alumina. Again, softening of dentine by an erosive challenge will increase susceptibility of the tissue to wear.
Dentine is a vital tissue that in vivo is normally covered by enamel or cementum depending on the location i.e. crown versus root respectively. Dentine has a much higher organic content than enamel and its structure is characterised by the presence of fluid- filled tubules that run from the surface of the dentine-enamel or dentine-cementum junction to the odontoblast/pulp interface. It is widely accepted that the origins of dentine hypersensitivity relate to changes in fluid flow in exposed tubules, (the hydrodynamic theory), that result in stimulation of mechanoreceptors thought to be located close to the odontoblast/pulp interface. Not all exposed dentine is sensitive since it is generally covered with a smear layer; an occlusive mixture comprised predominantly of mineral and proteins derived from dentine itself, but also containing organic components from saliva. Over time, the lumen of the tubule may become progressively occluded with mineralised tissue. The formation of reparative dentine in response to trauma or chemical irritation of the pulp is also well documented. Nonetheless, an erosive challenge can remove the smear layer and tubule "plugs" causing outward dentinal fluid flow, making the dentine much more susceptible to external stimuli such as hot, cold and pressure. As previously indicated, an erosive challenge can also make the dentine surface much more susceptible to wear. In addition, dentine hypersensitivity worsens as the diameter of the exposed tubules increases, and since the tubule diameter increases as one proceeds in the direction of the odontoblast/pulp interface, progressive dentine wear can result in an increase in hypersensitivity, especially in cases where dentine wear is rapid.
Loss of the protective enamel layer through erosion and/or acid-mediated wear will expose the underlying dentine, and are therefore primary aetiological factors in the development of dentine hypersensitivity.
It has been claimed that an increased intake of dietary acids, and a move away from formalised meal times, has been accompanied by a rise in the incidence of dental erosion and tooth wear. In view of this, methods which help prevent dental erosion and tooth wear would be advantageous.
EPl 568 356A (Sara Lee), relates to the use of colostrum protein in oral care compositions for the prevention or reduction of dental erosion. The oral care compositions containing from 0.5 to 2.0mg colostrum protein were shown to inhibit hydroxyapatite dissolution in 1OmM nitric acid, pH 5.0.
WO06/056013 (University of Melbourne), relates to a phosphopeptide-stabilised amorphous calcium phosphate and/ or amorphous calcium fluoride phosphate complex useful in dental applications, including anti-erosion/corrosion, and in particular dental remineralisation.
The present invention is based on the discovery that certain proteins have the ability to combat (i.e. help to prevent, inhibit and/or treat) dental erosion caused by the intake of dietary acids.
The present invention provides the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein in the manufacture of an oral care composition for combating dental erosion and/or tooth wear caused by subsequent exposure to acid i.e exposure to acid following administration of the protein(s). In another aspect the present invention provides an oral care composition comprising a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for use in combating dental erosion and / or tooth wear caused by subsequent exposure to acid. In one embodiment the protein is casein.
The protein for use in oral care compositions according to the invention is present in an amount of from 0.001% w/v to 10.0 % w/v, suitably 0.01% w/v to 5.0 % w/v, more suitably 0.10% w/v to 2.0% w/v.
Suitably the protein for use in the present invention is derived from natural sources.
Casein and whey protein are typically extracted from whole milk. Whey protein is a byproduct of cheese manufacture. Ovalbumin is typically extracted from avian eggs, for example, chicken's eggs. Soy protein is typically extracted from soy beans.
An advantage presented by oral care compositions containing protein according to the invention, is that teeth when pre-treated with a composition according to the invention are protected against the damaging effect of subsequent exposure to dietary acid, typically in the pH range 2.0 to 4.5.
The term pre-treatment or pre-treated as used herein refers to treatment of the teeth with a composition comprising the protein prior to exposure to an acid.
Oral care compositions containing protein according to the invention will contain appropriate formulating agents such as abrasives, surfactants, thickening agents, humectants, flavouring agents, sweetening agents, opacifying or colouring agents, preservatives and water, selected from those conventionally used in the oral care composition art for such purposes. Examples of such agents are as described in EP 929287.
Preferably compositions containing protein for use according to the invention will further comprise a source of soluble fluoride ions such as those provided by sodium fluoride, sodium monofluorophosphate, tin (II) fluoride or an amine fluoride in an amount to provide from 25ppm to 3500 ppm fluoride, preferably from lOOppm to 1500 ppm.
Additional oral care actives may be included in the compositions containing protein according to the invention.
Oral care compositions containing protein for use according to the invention are typically formulated in the form of toothpastes, sprays, mouthwashes, gels, lozenges, chewing gums, tablets, pastilles, instant powders, oral strips or buccal patches.
The compositions containing protein for use according to the invention may be prepared by admixing the ingredients in the appropriate relative amount in any order that is convenient, and if necessary adjusting the pH to give a desired value for example from pH 5.5 to 9.0, suitably from pH 6.5 to 7.5.
In another aspect of the present invention there is provided a method of combating dental erosion and / or tooth wear caused by subsequent exposure to acid which comprises applying an effective amount of an oral care composition as hereinbefore defined to an individual in need thereof.
The present invention is illustrated by way of the following non-limiting examples.
Example 1. To Demonstrate the Pre-treatment effect of a Composition Comprising Casein.
Materials and Method
Hydroxyapatite dissolution measurements
An automatic titration system (Metrohm, Buckingham, UK), equipped with a 50 mL water-jacketed reaction vessel was set up to maintain constant pH by addition of 50 mmol/L HCl. The reaction temperature was 36°C. Hydroxyapatite was employed as an analogue of dental enamel ( Barbour and Rees (2004) J. Dentistry 32: 591-602). Hydroxyapatite (HA) discs (Hitemco Medical Applications, Old Bethpage, USA), 12.05 mm in diameter x 1.25 mm thick were fixed to a glass rod using sticky wax and the underside of the disc coated with nail varnish to give a constant exposed area of 155.5 mm2 for each disc. The glass rod carrying the disc was fixed to a tube which fitted the inlet port of the reaction vessel lid and which held the specimen in a reproducible position with respect to the stirrer. For each dissolution measurement 15 mL of test solution was placed in the reaction vessel and stirred with a magnetic stirrer. When the temperature and pH had reached equilibrium the reaction was initiated by immersing the HA disc into the solution. Acid addition was linear with time and the rate of acid addition was used as the measure of HA dissolution.
New discs were conditioned by exposing them to stirred control citric acid solution for 30 min to remove any loosely attached or more soluble material. For every measurement, a control run and a test run were performed. The dissolution rate of an HA disc in the control citric acid solution was measured first and then the dissolution rate of the same HA disc in the test solution. Every measurement thus had its own control. Each test solution was tested three times. After a disc had been exposed to a protein test solution it was discarded.
To evaluate the persistence of the action of the protein against acid erosion, sequential measurements were performed. After conditioning the discs, three control runs of 30 minutes in the control citric acid solution were performed to obtain a mean baseline measurement. After this a single run of 2 minutes was performed with 0.10% w/v casein, pH 6.5. The discs were then washed and followed by sequential 30 minute runs in the control acid solution (pH 3.2) until the dissolution rate reached the baseline level. Each persistence of action experiment was performed at least three times with 0.10 % w/v protein, each sequence being run on a separate HA disc.
Results
Figure 1. Hydroxyapatite dissolution 0.3% w/v Citric acid, pH 3.2 over 240 min before and after 0.10% w/v casein exposure.
Figure imgf000008_0001
Table 1. Hydroxyapatite dissolution 0.3% w/v Citric acid, pH 3.2 over 240 min before and after 0.10% w/v casein exposure. (Standard deviation in brackets).
Figure imgf000008_0002
Summary Example 1. demonstrates the pre-treatment effect where an inhibitory effect of casein against acid damage is apparent even after continuous immersion of the specimen in citric acid for 2.5 h. Example 2. Typical Dentifrice Formulation - 2.0% w/v Protein
Figure imgf000009_0001

Claims

CLAIMS 1. The use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein or a mixture thereof in the manufacture of an oral care composition for combating dental erosion and/or tooth wear caused by subsequent exposure to acid.
2. Use according to claim 1 wherein the protein is present in an amount from 0.001 % w/v to 10.0 % w/v.
3. Use according to claim 1 or 2 wherein the oral care composition further comprises a source of fluoride ions.
4. An oral care composition comprising a protein selected from one or more of casein, ovalbumin, whey protein and soy protein combating dental erosion and / or tooth wear caused by subsequent exposure to acid.
5. An oral care composition according to claim 4 wherein the protein is present in an amount from 0.001% w/v to 10.0 % w/v.
6. An oral care composition according to claim 4 or 5 further comprising a source of fluoride ions.
7. A method of combating dental erosion and / or tooth wear caused by subsequent exposure to acid which comprises applying an effective amount of an oral care composition as defined in claims 1 to 6 to an individual in need thereof.
PCT/EP2008/066314 2007-11-30 2008-11-27 Oral care compositions comprising casein, ovalbumin, whey or soy protein Ceased WO2009068602A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/744,881 US20110052507A1 (en) 2007-11-30 2008-11-27 Oral care compositions comprising casein, ovalbumin, whey or soy protein
EP08853669A EP2214695A2 (en) 2007-11-30 2008-11-27 Novel use
CA2706800A CA2706800A1 (en) 2007-11-30 2008-11-27 Novel use
JP2010535375A JP2011504910A (en) 2007-11-30 2008-11-27 Oral care composition comprising casein, ovalbumin, whey protein or soy protein
AU2008328832A AU2008328832A1 (en) 2007-11-30 2008-11-27 Oral care compositions comprising casein, ovalbumin, whey or soy protein
BRPI0820367 BRPI0820367A2 (en) 2007-11-30 2008-11-27 Use of a protein, oral care composition, and method for combating tooth erosion and / or tooth wear.
MX2010005922A MX2010005922A (en) 2007-11-30 2008-11-27 Novel use.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0723523.7 2007-11-30
GBGB0723523.7A GB0723523D0 (en) 2007-11-30 2007-11-30 Novel use

Publications (2)

Publication Number Publication Date
WO2009068602A2 true WO2009068602A2 (en) 2009-06-04
WO2009068602A3 WO2009068602A3 (en) 2009-08-06

Family

ID=38962444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/066314 Ceased WO2009068602A2 (en) 2007-11-30 2008-11-27 Oral care compositions comprising casein, ovalbumin, whey or soy protein

Country Status (9)

Country Link
US (1) US20110052507A1 (en)
EP (1) EP2214695A2 (en)
JP (1) JP2011504910A (en)
AU (1) AU2008328832A1 (en)
BR (1) BRPI0820367A2 (en)
CA (1) CA2706800A1 (en)
GB (1) GB0723523D0 (en)
MX (1) MX2010005922A (en)
WO (1) WO2009068602A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025099450A1 (en) * 2023-11-10 2025-05-15 Lintbells Limited Dental paste

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101950661B1 (en) * 2011-09-28 2019-02-20 라이온 가부시키가이샤 Oral composition
US11213466B2 (en) * 2014-12-26 2022-01-04 Colgate-Palmolive Company Personal care compositions with zinc phosphate active

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199891A (en) * 1981-03-04 1985-07-31 Univ Melbourne Caries-inhibiting compositions containing casein or x-s-casein or phosuitin
US5130123A (en) * 1981-03-04 1992-07-14 The University Of Melbourne Dentifrice
JPS61130214A (en) * 1984-11-30 1986-06-18 Sunstar Inc Tooth paste composition free from surface active agent
JPH0441417A (en) * 1990-06-01 1992-02-12 Kanebo Ltd Composition for oral cavity
JP3545002B2 (en) * 1992-12-12 2004-07-21 太陽化学株式会社 Oral hygiene products
CH684773A5 (en) * 1992-12-28 1994-12-30 Nestle Sa anti-cariogenic food composition.
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US5853704A (en) * 1997-09-22 1998-12-29 Colgate-Palmolive Company Fluoride dentifrices of enhanced efficacy
AUPP494798A0 (en) * 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US20040057908A1 (en) * 2001-12-13 2004-03-25 Bowen William H. Oral compositions and use thereof
US7087228B2 (en) * 2002-07-03 2006-08-08 University Of Southern California Preventing tooth decay and infective endocarditis using natural oligopeptides
US7074390B2 (en) * 2003-03-06 2006-07-11 Mackinnon Carol L Encapsulated dentifrice and method of use
WO2005023210A1 (en) * 2003-09-05 2005-03-17 Kabushiki Kaisha Sangi Recalcification-promoting agent, oral composition, food and drink
RU2280437C2 (en) * 2004-08-05 2006-07-27 Совместное открытое акционерное общество "Парфюмерно-косметическая фабрика "Модум - наша косметика" Tooth paste with whey
EP1625877A3 (en) * 2004-08-09 2006-03-08 Friesland Brands B.V. Functional milk fraction
EP1627570A1 (en) * 2004-08-19 2006-02-22 Wageningen Centre for Food Sciences Egg protein compositions, their preparation and their use for cold or heat gelation
US20060105025A1 (en) * 2004-11-15 2006-05-18 Hill Ira D Recovery pet chews

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025099450A1 (en) * 2023-11-10 2025-05-15 Lintbells Limited Dental paste

Also Published As

Publication number Publication date
GB0723523D0 (en) 2008-01-09
WO2009068602A3 (en) 2009-08-06
CA2706800A1 (en) 2009-06-04
JP2011504910A (en) 2011-02-17
AU2008328832A1 (en) 2009-06-04
MX2010005922A (en) 2010-10-04
BRPI0820367A2 (en) 2015-05-12
EP2214695A2 (en) 2010-08-11
US20110052507A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
US9744108B2 (en) Methods and compositions for preventing and treating tooth erosion
Durhan et al. Caries Preventive Effects of Theobromine Containing Toothpaste on Early Childhood Caries: Preliminary Results.
JP7330098B2 (en) Oral composition capable of promoting tooth remineralization
EP1868689B1 (en) Alkyl sulfate free and orthophosphate free dentifrice composition comprising a fluoride source and a silica dental abrasive
US20110052507A1 (en) Oral care compositions comprising casein, ovalbumin, whey or soy protein
US20100316579A1 (en) Novel use of alkyl phosphate esters
JP5709639B2 (en) Oral composition
US20220354774A1 (en) Toothpaste for preventing cold teeth and periodontal diseases and manufacturing method therefor
US9259379B2 (en) Oral care compositions for combatting dental erosion
Morozova et al. Tooth wear-fundamental mechanisms and diagnosis
Goel et al. Microabrasion-a conservative approach for mild to moderate fluorosis–a case report
EP2167020A1 (en) Mouthwash composition comprising xanthan gum and sodium fluoride
WO2007065856A1 (en) Oral compositions comprising rod-shaped apatite nanocrystals
WO2023285797A1 (en) Oral care compositions with phosphopeptides for use against dental hypersensitivity and/or xerostomia
WO2005023210A1 (en) Recalcification-promoting agent, oral composition, food and drink
Bhushan et al. Tooth Wear-An Overview With Special Emphasis On Dental Erosion.
CN121793979A (en) Oral care compositions for treating dental health conditions
Jathanna et al. Original
Abdul-Jabbar Teeth Wear
Vujkov et al. ADVANCES IN MODERN PREVENTIVE DENTISTRY
Efka et al. PREVENTION OF WHITE SPOT LESIONS DURING ORTHODONTIC TREATMENT
Feltham The Power of Sour Candies.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08853669

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008853669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2706800

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010535375

Country of ref document: JP

Ref document number: MX/A/2010/005922

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008328832

Country of ref document: AU

Date of ref document: 20081127

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0820367

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100527